Cloud-Clone expands small-molecule ELISA portfolio after decade of R&D

Cloud-Clone says more than 10 years of work helped it solve key technical hurdles in small-molecule detection and build a larger menu of ELISA kits for research use. The company says the kits are gaining academic traction and could reduce reliance on slower, instrument-heavy testing methods.

Why it matters: - Small-molecule detection remains a major bottleneck in biomedical research because many analytes below 1,000 daltons are hard to turn into antibodies and hard to measure with standard immunoassays. - Cloud-Clone says its progress could make research testing faster, less instrument-dependent and more accessible for academic and laboratory users. - The company is targeting analytes with research, clinical and food-safety relevance, including glutathione, melatonin, estradiol, insulin and clenbuterol.

What happened: - Cloud-Clone said on September 21, 2026, that it has spent more than a decade developing small-molecule ELISA kits through independent R&D. - The company says it has built a mature portfolio of kits for small-molecule biomarker measurement. - Cloud-Clone said its small-molecule ELISA kits now cover multiple analytes, including malondialdehyde, estradiol, testosterone, T3 and melatonin. - The company said its T3 kit is one example of the platform’s progress.

The details: - Small molecules lack intrinsic immunogenicity, which makes direct animal immunization ineffective for producing target-specific antibodies. - Traditional testing often depends on high-performance liquid chromatography and gas-chromatography-mass spectrometry, which require expensive instruments and extensive sample preparation. - Cloud-Clone said its team first tried classic carboxyl-amino coupling for T3, but the approach damaged the native structure or produced antibodies with weak specificity. - Researchers then shifted to a structural-optimization approach inspired by small-molecule immunomodulator research. - The team blocked T3’s carboxyl group through esterification and then used succinic anhydride to create carboxylated hapten derivatives. - Cloud-Clone said the workflow produced positive experimental results and helped move the program forward. - The company said it completed hundreds of similar modification trials across several analytes and used iterative testing to identify the best scheme for each target. - After the modification work, the team built competitive-inhibition ELISA systems, since small molecules are too small for sandwich-format ELISA. - Researchers screened antigen-antibody pairs, refined assay parameters and monitored microplate-reader results in shifts until they produced standard curves. - Cloud-Clone said it has ISO9001:2015 and ISO13485:2016 certifications and operates a licensed SPF-grade laboratory-animal facility. - The company said its in-house control spans animal breeding through finished-reagent manufacturing. - The company also points to a standard curve for its T3 ELISA kit as part of the product validation package.

Between the lines: - The announcement is as much about platform-building as it is about a single kit, with Cloud-Clone trying to turn one-off assay development into a repeatable small-molecule pipeline. - The citation comparison suggests the company wants to position its kits against established international suppliers such as R&D and Abcam. - The use of academic citations as proof points signals that Cloud-Clone is leaning on research adoption, not just product claims, to argue market credibility.

What's next: - Cloud-Clone said it will keep expanding biological-reagent innovation as demand for small-molecule detection tools grows. - The company said it aims to deliver additional high-quality research products and raise the profile of independently developed biological reagents globally. - Researchers and labs can find more information at Cloud-Clone's website.

The bottom line: - Cloud-Clone says it has moved small-molecule ELISA development from a technical challenge to a scalable product line, with early signs of academic adoption and broader research use.